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Src homology 2 (SH2) domains exist in many intracel-
lular proteins and have well characterized roles in sig-
nal transduction. SH2 domains bind to phosphotyrosine
(Tyr(P))-containing proteins. Although tyrosine phos-
phorylation is essential for protein-SH2 domain interac-
tions, the binding specificity also derives from se-
quences C-terminal to the Tyr(P) residue. The high
affinity and specificity of this interaction is critical for
precluding aberrant cross-talk between signaling path-
ways. The p85a subunit of phosphoinositide 3-kinase (PI
3-kinase) contains two SH2 domains, and it has been
proposed that in competition with Tyr(P) binding they
may also mediate membrane attachment via interac-
tions with phosphoinositide products of PI 3-kinase. We
used nuclear magnetic resonance spectroscopy and bio-
sensor experiments to investigate interactions between
the p85a SH2 domains and phosphoinositides or inositol
polyphosphates. We reported previously a similar ap-
proach when demonstrating that some pleckstrin ho-
mology domains show binding specificity for distinct
phosphoinositides (Salim, K., Bottomley, M. J., Quer-
furth, E., Zvelebil, M. J., Gout, I., Scaife, R., Margolis,
R. L., Gigg, R., Smith, C. I., Driscoll, P. C., Waterfield,
M. D., and Panayotou, G. (1996) EMBO J. 15, 6241–6250).
However, neither SH2 domain exhibited binding speci-
ficity for phosphoinositides in phospholipid bilayers.
We show that the p85a SH2 domain Tyr(P) binding pock-
ets indiscriminately accommodate phosphoinositides
and inositol polyphosphates. Binding of the SH2 do-
mains to Tyr(P) peptides was only poorly competed for
by phosphoinositides or inositol polyphosphates. We
conclude that these ligands do not bind p85a SH2 do-
mains with high affinity or specificity. Moreover, we
observed that although wortmannin blocks PI 3-kinase
activity in vivo, it does not affect the ability of tyrosine-
phosphorylated proteins to bind to p85a. Consequently
phosphoinositide products of PI 3-kinase are unlikely to
regulate signaling through p85a SH2 domains.
Src homology 2 (SH2)1 domains are conserved, noncatalytic
sequences of about 100 amino acids that adopt a common
three-dimensional fold. These domains are commonly found in
signal transduction proteins that regulate a variety of cellular
processes, such as phospholipid metabolism, protein phospho-
rylation, and dephosphorylation, protein trafficking, and gene
expression (1). SH2 domains mediate high affinity binding to
phosphotyrosine (Tyr(P)) residues in proteins such as activated
membrane receptors and cytosolic adaptor proteins. Three to
five amino acids C-terminal to the target Tyr(P) residue bind to
a groove on the SH2 domain surface and confer the specificity
of interaction that is necessary to avoid aberrant signaling (2,
3). The role of SH2 domains in Tyr(P)-dependent protein re-
cruitment is critical for the assembly of active complexes of
signaling proteins (4, 5).
The p85a/p110a Class IA phosphoinositide 3-OH kinase (PI
3-kinase) contains two SH2 domains in its regulatory p85a
subunit (6). Upon cell stimulation, the SH2 domains bind to
tyrosine-phosphorylated, membrane-bound growth factor re-
ceptors. As a result, p85a/p110a is recruited to the vicinity of
its phosphoinositide substrates (7). The p110a PI 3-kinase ac-
tivity then produces 39-phosphorylated phosphoinositides. In
this manner, p85a/p110a mediates a dramatic increase in the
basal concentration of phosphatidylinositol 3,4,5-trisphosphate
(PtdIns (3,4,5)P3) and phosphatidylinositol 3,4-bisphosphate in
the plasma membrane shortly after cell stimulation (8, 9).
It is now clear that p85a/p110a phosphorylates phosphoi-
nositides to produce second messengers, which control the
membrane recruitment and activation of numerous signaling
proteins, notably including regulators of apoptosis (10–12).
Many of the target proteins of these second messengers contain
pleckstrin homology (PH) domains and have been shown to
bind specifically to PtdIns (3,4,5)P3 and/or phosphatidylinositol
3,4-bisphosphate in vitro and/or in vivo (13–19). Indeed, nu-
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merous interactions between distinct phosphoinositides and
PH domains have now been demonstrated and appear to be
essential for the function of various cytoskeletal or signal
transduction proteins (reviewed in Ref. 20).
However, a few reports have suggested that PH domains are
not unique targets of second messenger phosphoinositides pro-
duced by PI 3-kinase. It has been proposed that PtdIns
(3,4,5)P3 can also bind to SH2 domains. These proposals fol-
lowed the observation of an inverse correlation between the
amount of p85a/p110a associated with tyrosine-phosphoryl-
ated proteins and the level of PI 3-kinase lipid products present
in the cell (21). Consequently, a model was proposed in which
the PtdIns (3,4,5)P3 produced by PI 3-kinase activation could
compete for Tyr(P)-bound p85a SH2 domains and directly re-
sult in the relocalization of p85a/p110a at the plasma mem-
brane. Similarly, the production of PtdIns (3,4,5)P3 may regu-
late additional proteins such as the tyrosine kinase Src and
phospholipase C g-1 (21, 22). It has been shown that in vitro the
p85a C-terminal SH2 (C-SH2) domain can bind to PtdIns
(3,4,5)P3 (21). However, it was not demonstrated that recom-
binant p85a C-SH2 domain can act as a faithful model of p85a
activity. Indeed, we noted with intrigue that the reported in-
teraction of PtdIns (3,4,5)P3 with the p85a C-SH2 domain could
be significantly inhibited by phenyl phosphate, but that such
inhibition was not observed in the case of the reported inter-
action between PtdIns (3,4,5)P3 and full-length p85a (21). The
work presented herein arose from our attempts to clarify these
apparently conflicting observations and to resolve certain is-
sues central to these models describing distinct phosphoinosit-
ide-SH2 domain interactions.
Prerequisites for the models above are that the SH2 domains
that interact with phosphoinositides must (a) demonstrate a
significant binding affinity for these ligands and (b) discrimi-
nate between the numerous phosphoinositides present in the
plasma membrane. Because we had access to appropriate re-
agents and assay techniques, we set out to determine whether
the p85a SH2 domains indeed display clear binding specificity
and affinity for distinct phosphoinositides. We report the first
high resolution structural studies of model phosphoinositide-
SH2 domain interactions, which we performed by nuclear mag-
netic resonance (NMR) spectroscopy. We also employed two
sensitive biosensor assays; one to measure interactions be-
tween proteins and phospholipid bilayers containing phosphoi-
nositides and another to measure directly the competition be-
tween Tyr(P)-containing ligands and phosphoinositides for
binding to SH2 domains. In addition, we report in vivo studies
in which we sought a correlation between the association of
p85a with activated growth factor receptors or tyrosine-phos-
phorylated proteins and the intracellular level of PI 3-kinase
products.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The p85a C-SH2 domain (amino acids Glu-614–Arg-724) was ex-
pressed and purified as described previously (23). A pGEX-2T plasmid
encoding glutathione S-transferase (GST) (Amersham Pharmacia Bio-
tech) fused to the p85a N-terminal SH2 (N-SH2) domain (amino acids
Pro-314—Tyr-431) was kindly provided by Dr. R. Stein (Ludwig Insti-
tute for Cancer Research, London), and the protein was prepared and
purified essentially as described previously (24, 25). Transformed Esch-
erichia coli BL21 (DE3) cells were grown at 37 °C to a culture density
A600 ; 0.8. Protein expression was induced by the addition of isopropyl-
1-thio-b-D-galactopyranoside to a concentration of 0.2 mM. Cells were
harvested after 4 h, resuspended in phosphate-buffered saline (PBS),
and lysed by a French press. For NMR spectroscopy and biosensor
Tyr(P) competition assays, the GST moiety was removed by thrombin
cleavage. In contrast, intact fusion protein was used in the liposome
binding assays. Further protein purification was accomplished by gel
filtration in 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.02% NaN3.
15N-
isotopically enriched samples for NMR spectroscopy were prepared as
above except that cells were grown in a minimal M9 medium using
15NH4Cl (Isotec Inc.) as the sole nitrogen source. NMR samples were
prepared in 50 mM deuterated Tris-HCl (Cambridge Isotope Laborato-
ries), pH 7.5, 50 mM NaCl, 2 mM dithiothreitol (for C-SH2 only), 10%
(v/v) D2O.
Ligands Tested for Binding to p85a SH2 Domains
The water-soluble ligands tested included D-myo-inositol 1,4,5-
trisphosphate (D-Ins (1,4,5)P3), L-Ins (1,4,5)P3, L-a-glycerophospho-D-
myo-inositol 4,5-bisphosphate, and phenyl phosphate obtained from
Sigma; D-Ins (1,3,4,5)P4 and L-Ins (1,3,4,5)P4, synthesized and purified
by ion-exchange chromatography as published (26, 27); rac-dihex-
anoylphosphatidyl-D/L-myo-inositol 3,4,5-trisphosphate (di-C6-PIP3),
synthesized using published techniques (28); and the nine-residue
phosphopeptide SVDY(P)VPMLD (Y(P) is phosphotyrosine) (Genosys
Ltd.). The phospholipids tested included PtdIns, PtdIns (4)P, and Pt-
dIns (4, 5)P2 (obtained from Lipid Products, Redhill, Surrey, UK) and
PtdIns (3,4,5)P3, which was prepared as described previously (29) and
kindly provided by Professor R. Gigg. The additional liposome compo-
nents described were purchased from Sigma.
NMR Spectroscopy Experiments
For NMR spectroscopy, SH2 domain samples were prepared at 0.5
mM concentration in 600 ml. Interactions were monitored via spectra
recorded during titration of the SH2 domain with 1.5-ml aliquots of test
ligand (prepared at 20 mM in 20 mM Tris-HCl, pH 7.5, 50 mM NaCl).
NMR experiments were performed at 15 °C on a Varian UNITY-plus
spectrometer operating at a 1H frequency of 600 MHz. Two-dimensional
gradient enhanced sensitivity 15N-1H heteronuclear single quantum
coherence (HSQC) experiments were performed using a pulse sequence
kindly provided by Professor L. E. Kay (30). Sign discrimination in t1
was achieved using the States-time-proportional phase incrementation
method. The HSQC spectra were acquired with 16 scans, 64 increments
in t1, and sweep widths of 10000 Hz (
1H) and 2400 Hz (15N). Three-
dimensional 15N-1H HSQC total correlation spectroscopy and nuclear
Overhauser effect spectroscopy experiments were recorded to verify the
published resonance assignments for the N-SH2 domain (31, 32).
NMR data were processed using NMRpipe software (33). Phase-
shifted, sine-squared shaped weighting functions and zero-filling were
applied before Fourier transformation. NMR spectra were analyzed
using XEASY (34) and AZARA software (AZARA v.II, W. Boucher,
Department of Biochemistry, University of Cambridge, UK).
Biosensor Experiments
Preparation of Liposomes for Biosensor Studies—Large unilamellar
liposomes with a phospholipid composition approximating the inner
leaflet of the plasma membrane were prepared as described previously
(35). By weight, the liposomes contained 30% phosphatidylcholine, 15%
sphingomyelin, 20% cholesterol, 15% phosphatidylethanolamine, 10%
phosphatidylserine, and 10% of the phosphoinositide to be tested. Li-
posomes were used in 10 mM HEPES, pH 7.4, 80 mM KCl, 15 mM NaCl,
0.7 mM NaH2PO4, 1 mM EGTA, 0.466 mM CaCl2, 2.1 mM MgCl2.
Liposome Binding Studies Using the Biosensor—The basic operating
procedures of the surface plasmon resonance BIAcore biosensor (BIA-
CORE AB, Uppsala) have been published (36). The ability of immobi-
lized GST fusion SH2 domains to bind to phosphoinositides in liposomes
was examined using the method described previously (35).
Phosphoinositide Phosphotyrosine Peptide Competition Studies Us-
ing the Biosensor—A precoated streptavidin biosensor chip (SA-5, BIA-
CORE AB) was used to immobilize the N-terminal-biotinylated, Tyr(P)
peptide N-biotinyl-DMSKDESVDY(P)VPMLDMK (Y(P) is phosphoty-
rosine). The Tyr(P) peptide was loaded in the buffer used throughout
the assay: 20 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005%
Tween 20, and 4 mM dithiothreitol. Solutions of 0.5 mM N- or C-SH2
domain were injected over the surface at a flow rate of 5 ml/min at 25 °C,
and the maximum response was recorded. Competition experiments
were performed by incubating the SH2 domains with a competitor
ligand before injection. Efficacious competition resulted in a diminished
response. Between injections, protein remaining bound to the biosensor
was removed by a 5-ml pulse of 0.05% SDS solution.
Data analysis of the competition measurements was performed with
the BIAcore-2000 software package (BIACORE AB). In calculations of
the half-maximal inhibitory constants (IC50), the control response from
injection of SH2 domain over the biosensor surface lacking the Tyr(P)
peptide was subtracted from the experimental response to yield the
corrected response, R. Data was plotted as corrected response units
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versus concentration of competitor and were fitted to the following
equation using a nonlinear least-squares analysis: R 5 Rmax/[1 1 (C/
IC50)
P], where Rmax is the response for SH2 binding in the absence of
competitor, C is the concentration of competitor, and P is the Hill
coefficient.
In Vivo Assays
Cell Culture—Mouse NIH3T3 fibroblasts were grown at 37 °C in a
humidified atmosphere containing 10% CO2 in Dulbecco’s modified
Eagle’s medium (Life Technologies, Inc.) supplemented with 10% (v/v)
heat-inactivated fetal calf serum (Life Technologies, Inc.) and penicillin/
streptomycin (Life Technologies, Inc.). The cells were grown to conflu-
ence in 150-mm dishes and serum-starved in Dulbecco’s modified Ea-
gle’s medium containing 0.5% (v/v) heat-inactivated fetal calf serum for
16 h.
Immunoprecipitations—Cells grown on 150-mm dishes were incu-
bated for 15 min at 37 °C with wortmannin (100 nM in Me2SO) or an
equivalent volume of Me2SO and subsequently stimulated with recom-
binant PDGF-b (100 nM) for 10 min at 37 °C. The dishes were then
placed on ice, washed once in ice-cold PBS buffer (Life Technologies,
Inc.), and lysed for 20 min on ice in 1 ml of lysis buffer (20 mM
HEPES/NaOH, pH 7.4, 150 mM NaCl, 1%(w/v) Triton X-100, 2 mM
EDTA, 10 mM NaF, 10 mM Na2HPO4, 10% (w/v) glycerol, 1 mM phen-
ylmethylsulfonyl fluoride, 5 mM benzamidine, 7 mM diisopropylphos-
phofluoridate, 1 mM 1-chloro-3-tosylamido-7-amino-2-heptanone, 20 mM
leupeptin, 18 mM pepstatin, 21 mg/ml aprotinin, 2 mM dithiothreitol, 1
mM Na3VO4, 10 mM b-glycerophosphate, 1 mM tetrasodium pyrophos-
phate, 1 mM sodium molybdate). The cells were then scraped from the
dishes and centrifuged for 20 min at 15,000 3 g and 4 °C. The super-
natant was collected and incubated with the relevant antibody with
constant agitation at 4 °C for 2 h. Protein G-Sepharose CL-4B (Amer-
sham Pharmacia Biotech) at 10 ml of bead slurry/sample was then
added, and the incubation continued for 1 h at 4 °C on a wheel. The
immunoprecipitates were washed three times in lysis buffer and ana-
lyzed by SDS-polyacrylamide gel electrophoresis and Western blotting
or assayed for PI 3-kinase activity.
PI 3-Kinase Assays—PI 3-kinase activity was assayed on immuno-
precipitates resuspended in 25 ml of 23 kinase buffer (40 mM Tris-HCl,
pH 7.4, 200 mM NaCl, 2 mM dithiothreitol). PtdIns stored in CHCl3
solution was dried, sonicated for 15 min in 50 mM Tris-HCl, pH 7.4, and
added to a concentration of 0.2 mg/ml. The reactions (50-ml final vol-
ume) were started by the addition of 40 mM ATP, 10 mCi of [g-32P ]ATP
(3000 Ci/mmol, Amersham Pharmacia Biotech), and 3.5 mM MgCl2.
Kinase reactions were stopped by the addition of 100 ml of 1 M HCl. For
phospholipid extraction, 200 ml of 1:1 (v/v) CHCl3/CH3OH was added.
The organic phase was collected and re-extracted with 40 ml of 1:1 (v/v)
1 N HCl/CH3OH. The samples were then dried, resuspended in 30 ml of
CHCl3/ CH3OH 1:1 (v/v), and spotted onto prechanneled silica gel 60
TLC plates (Whatman) that had been pretreated in 1% (w/v) oxalic acid,
1 mM EDTA, H2O/CH3OH (60:40 (v/v) and baked for 15 min at 110 °C.
The plates were developed in propanol, 2 M acetic acid 65:35 (v/v), and
the radioactive spots were quantified using a PhosphorImager (Molec-
ular Dynamics).
Western Blotting—After SDS- polyacrylamide gel electrophoresis,
polyacrylamide gels (7.5%) were transferred onto polyvinylidene diflu-
oride membranes (Gelman Sciences) using a semi-dry blotter (Amer-
sham Pharmacia Biotech). The membranes were then blocked for 1 h in
PBS buffer containing 3% (w/v) nonfat dry milk, 0.1% (w/v) polyethyl-
ene glycol 20000. The relevant primary antibodies were diluted in PBS
buffer and 0.05% (w/v) Tween 20 (PBS/Tween) and incubated with the
membranes for 2 h. After extensive washing in PBS/Tween, the blots
were incubated for 1 h with goat anti-mouse or anti-rabbit antibodies
coupled to horseradish peroxidase (Dako) at 1:2000 dilution. The mem-
branes were then washed in PBS/Tween, and the bands were detected
using ECL (Amersham Pharmacia Biotech).
RESULTS
The Identification by NMR Spectroscopy of a Binding Site for
Phosphoinositides and Inositol Polyphosphates on the p85a
SH2 Domains—NMR spectroscopy was used to investigate the
structural details of the interactions between the p85a SH2
domains and a range of candidate phosphoinositide and inositol
polyphosphate ligands. 15N-1H HSQC NMR spectra were re-
corded during titrations of 15N-labeled SH2 domain with unla-
beled test ligands. It is well established that observations of
chemical shift perturbations upon titration with a ligand can be
a sensitive probe of the ligand binding site of a protein (37, 38).
During the titration, changes in 15N and 1H chemical shift
values for each residue were monitored by measuring changes
in the cross-peak positions of assigned resonances. For both
p85a SH2 domains, the introduction of any of the phosphoi-
nositide or inositol polyphosphate ligands tested resulted in
FIG. 1. NMR investigation of PI 3-kinase p85a subunit SH2 domains with inositol polyphosphate and phosphoinositide ligands.
Superimposed contour plots of highlighted regions of two-dimensional 1H-15N HSQC NMR spectra obtained from titrations of 0.5 mM 15N-labeled
samples of the p85a N-SH2 domain (A–E) and C-SH2 domain (F–I) with increasing ligand concentration (0–1.0 mM). The ligands used for each
experiment are D-InsP3 (A and F), D-InsP4 (B and G), L-InsP4 (C), di-C6-PIP3 (D and H), and phenyl phosphate (E and I). Cross-peaks represent
correlations between the 15N and 1H resonances of polypeptide backbone amide groups. A single contour level is plotted per step in the titration.
Only a subset of cross-peaks change position during the titrations. For each set of titrations, the same spectral region is shown, revealing that
di-C6-PIP3 and the inositol polyphosphates induce similar selective chemical shift perturbations in all titrations.
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significant chemical shift perturbations for a limited set of
cross-peaks (Fig. 1). For both the p85a N- and C-SH2 domains,
it was observed that the overall pattern of chemical shift
changes induced by the addition of the ligands are similar in
both direction and magnitude. The small differences in the
perturbation direction seen in the case of phenyl phosphate
(Fig. 1, panels E and I) result from additional ring-current shift
effects induced by its aromatic group. Most notably, there seem
to be very few differences when comparing the effects of D-Ins
(1,4,5)P3, D-Ins (1,3,4,5)P4, L-Ins (1,3,4,5)P4, or di-C6-PIP3. The
results with D-Ins (1,4,5)P3 and L-a-glycerophospho-D-myo-ino-
sitol 4,5-bisphosphate were also qualitatively similar to the
data obtained with the other inositol polyphosphates (data not
shown).
By mapping of the chemical shift perturbation data onto the
three-dimensional protein structures, the ligand binding sites
of the p85a N- and C-SH2 domains were determined. In all
cases, it was seen that the SH2 domain residues affected by the
ligands are similar and are localized to a discrete region of the
protein structure (Fig. 2). The results obtained for di-C6-PIP3,
the inositol polyphosphates, and phenyl phosphate show that
all these ligands bind to the region corresponding to the Tyr(P)
binding pocket seen in the high resolution structures of p85a
SH2 domains (39, 40). From quantitative analysis of the chem-
ical shift variation in the NMR studies, the equilibrium disso-
ciation constants (KD) of the interactions of the SH2 domains
with di-C6-PIP3 and inositol polyphosphates were found to be
between 0.5 and 1 mM. However, these averaged values contain
ranging contributions from different residues involved in the
binding and therefore are best considered as approximation
estimates. The absence of chemical shift perturbations for the
majority of SH2 domain resonances suggests that the ligands
tested neither induced long range conformational changes nor
resulted in local or global unfolding of the protein structure.
Phosphoinositides and Inositol Polyphosphates Compete
Poorly for the Binding of the p85a SH2 Domains to Tyrosine-
phosphorylated Proteins—Because the results from NMR spec-
troscopy showed that phosphoinositides and inositol polyphos-
phates can all bind to the Tyr(P) binding pockets of both p85a
SH2 domains, an assay was performed to assess whether these
interactions were sufficiently strong to displace Tyr(P)-contain-
ing ligands. A biosensor-based competition assay was used to
measure the binding of p85a SH2 domains to an immobilized
Tyr(P) peptide with the sequence DMSKDESVDY(P)VPM-
LDMK (Y(P) is phosphotyrosine). This phosphopeptide corre-
sponds to the autophosphorylation site at Tyr751 of the PDGF-b
receptor and is known to bind to both p85a SH2 domains with
high affinity (KD ; 200 nM) (3). The biosensor results revealed
that when present in relatively high concentrations, di-C6-PIP3
or any of the inositol polyphosphate ligands tested can compete
for the interaction between the p85a SH2 domains and the
immobilized Tyr(P) peptide ligand. However, it was readily
apparent that free Tyr(P) peptide was a much more effective
competitor than any of the other ligands tested, by a factor
;1000 (Fig. 3).
By curve-fitting the data to obtain IC50 values for the inter-
actions, it was observed that for each SH2 domain the phos-
phoinositide and inositol polyphosphates tested were similarly
FIG. 2. The ligand binding sites of
p85a SH2 domain revealed in NMR
titrations. Aligned structures of the
p85a N-SH2 domain (A) and C-SH2 do-
main (B), made using MOLSCRIPT (47),
Raster3D (48), and GRASP (49), are
shown. Secondary structure elements are
represented in schematic form. The blue
balls represent N-H groups, which dis-
played large chemical shift changes (mod-
ular vector sum 1H and 15N shift changes
.40 Hz) upon the addition of the ligand.
In all cases, the ligand binds between
a-helix A (23, 39) and the opposing face of
the b-sheet. In the upper left of each
panel, the SH2 domain surface is colored
by electrostatic potential to highlight the
positively charged ligand binding site
(blue); the red color corresponds to nega-
tively charged surface. This conserved
binding pocket is partly formed by a num-
ber of Arg and Lys residues, including the
invariant Arg at the bB5 position (23).
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competitive. Thus, no preference for ligand binding for either
SH2 domain was observed. For example, for the C-SH2 domain,
approximately the same IC50 values were obtained for di-C6-
PIP3, D-Ins (1,3,4,5)P4, L-Ins (1,3,4,5)P4, and D-Ins (1,4,5)P3
(Fig. 3, panels A and B and Table I). Although the N-SH2
domain exhibited a pattern of interactions similar to that of the
C-SH2 domain, the N-SH2 domain generally interacted even
more weakly with all the compounds tested (Fig. 3, panels C
and D). The IC50 values obtained for the phenyl phosphate
interactions were slightly smaller than for the phosphoinosit-
ide or inositol polyphosphate ligands but considerably larger
than for the free Tyr(P) peptide (Fig. 3 and Table I). The latter
result reflects that residues C-terminal to the Tyr(P) are also
essential for the known physiological high affinity interaction.
The p85a C-SH2 Domain Does Not Display Distinct Binding
Specificity for Phosphoinositides in Phospholipid Bilayers—
The results presented above did not suggest that the p85a SH2
domains undergo specific interactions with water-soluble phos-
phoinositide or inositol polyphosphate ligands. However, to
eliminate the possibility that the previous assays were not
representative of interactions with phosphoinositides available
in vivo, a second biosensor assay was performed. Using this
alternative assay, it was shown previously that the Btk PH
domain binds to phospholipid bilayers containing PtdIns
(3,4,5)P3 but not to those containing other negatively charged
phosphoinositides (35). Subsequently, this result has been sup-
ported by numerous reports of a high affinity interaction be-
tween the Btk PH domain and PtdIns (3,4,5)P3 or D-Ins
(1,3,4,5)P4 (15, 41, 42).
Thus, a second biosensor assay was performed to establish
whether the p85a C-SH2 domain could bind to specific phos-
phoinositides when presented in large unilamellar liposomes
(solely the C-SH2 domain was tested because the previous
assay yielded IC50 values that were smaller for the C-SH2
domain than for the N-SH2 domain). In brief, GST fusion SH2
domain was immobilized on an anti-GST antibody-coated sur-
face, as described previously (35). Solutions of liposomes with
differing phosphoinositide compositions were then injected
over the surface, and the responses were observed. The exper-
imental conditions used were exactly the same as those for the
previously reported study of phosphoinositide interactions with
the Btk PH domain (35). However, in contrast with the results
obtained for the Btk PH domain, the p85a C-SH2 domain did
not bind significantly to any of the phosphoinositide-containing
FIG. 3. Biosensor competition assay. Biosensor results showing the ability of ligand compounds to compete for the binding of p85a C-SH2
(panels A and B) and N-SH2 (panels C and D) domains to a tyrosine-phosphorylated ligand corresponding to the Tyr-751 (pY751) site of the
cytoplasmic domain of the PDGF receptor. IC50 values were determined by data fitting as described under “Experimental Procedures” and are
listed in Table I. Phe, phenyl
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liposomes tested. When the liposome injection dosages were
increased to more than 50 times the quantity sufficient to give
clear binding signals when assaying PH domains (35), it was
possible to observe a low level of nonspecific binding between
the SH2 domain and the entire array of liposomes tested.
However, the C-SH2 domain did not display a preference for
binding to liposomes containing PtdIns (3,4,5)P3 (Fig. 4). Fur-
thermore, it was observed that under these rather extreme
conditions, even a control GST protein exhibited a basal level of
nonspecific binding to all the liposomes tested (data not
shown).
However, in contrast with the results obtained for the Btk
PH domain, it was observed that the p85a C-SH2 domain did
not display a preference for binding to liposomes containing
PtdIns (3,4,5)P3 (Fig. 4). Indeed, the C-SH2 domain shows only
a low level of binding to an array of liposomes with different
phosphoinositide compositions, with no clear preference emerg-
ing for any of the phosphoinositides tested.
The Inhibition of PI 3-Kinase Activity Does Not Increase the
Levels of Phosphotyrosine-bound p85a in Vivo—After the in
vitro assays reported above, an in vivo experiment based on
that reported previously (21) was performed to search for a
correlation between the intracellular levels of Tyr(P)-bound
p85a and PI 3-kinase products. This involved measuring the
levels of p85a bound to the PDGF receptor and/or tyrosine-
phosphorylated proteins after cell stimulation in the presence
or absence of wortmannin. Because wortmannin inhibits PI
3-kinase activity (43), these experiments are taken to be in the
presence or absence of 39-phosphorylated phosphoinositides.
The stimulation of NIH3T3 fibroblasts by PDGF induced
both the association of p85a with the PDGF receptor (Fig. 5A)
and the appearance of p85a in anti-phosphotyrosine immuno-
precipitates (Fig. 5B), as judged by the anti-p85a immunoblot-
ting of anti-PDGF receptor and anti-phosphotyrosine immuno-
precipitates, respectively. These experiments were then
repeated, the only difference being the pretreatment of the
fibroblasts with 100 nM wortmannin. The wortmannin treat-
ment did not significantly affect the amount of p85a present in
either anti-PDGF receptor immunoprecipitates (Fig. 5A) or in
anti-phosphotyrosine immunoprecipitates (Fig. 5B). For con-
trol purposes, the efficacy of wortmannin with respect to PI
3-kinase inhibition was confirmed by the total inhibition of PI
3-kinase activity present in anti-phosphotyrosine immunopre-
cipitates after PDGF stimulation (Fig. 5C).
DISCUSSION
We sought to verify whether the products of PI 3-kinase
activity, 39-phosphorylated phosphoinositides, can interact
with the SH2 domains derived from the p85a regulatory sub-
unit of PI 3-kinase itself. Such interactions have been proposed
FIG. 4. Biosensor assay of p85a SH2
domain interactions with phosphoi-
nositide-containing liposomes. Biosen-
sor measurements for interactions between
liposomes and the p85a C-SH2 domain. The
specific phospholipid tested in the liposome
composition is indicated next to each sensor-
gram. PC, phosphatidylcholine
TABLE I
Inhibition of binding of phosphoinositide 3-kinase p85a subunit SH2
domains to an immobilized phosphotyrosine peptide in a biosensor
assay
N-Biotinyl-DMSKDESVDY(P)VPMLDMK (corresponding to the Tyr-
751 autophosphorylation site of the cytoplasmic domain of the platelet-
derived growth factor receptor) was fixed to a precoated streptavidin
biosensor chip. Solutions of 0.5 mM p85a N- or C-SH2 domain were
injected over the surface at a flow rate of 5 ml/min at 25 °C, and the
maximum response was recorded. Competition experiments were per-
formed by incubating the SH2 domains with a competitor ligand before
injection of the protein solution.
Protein Ligand testeda IC50
mM
C-SH2 Tyr(P)751 peptide 0.07 3 1023
C-SH2 di-C6-PIP3 1.4
C-SH2 D-InsP4 1.1
C-SH2 L-InsP4 1.1
C-SH2 D-InsP3 1.2
C-SH2 PhPO4 0.2
N-SH2 Tyr(P)751 peptide 0.59 3 1023
N-SH2 di-C6-PIP3 2.7
N-SH2 D-InsP4 2.7
N-SH2 L-InsP4 13.6
N-SH2 D-InsP3 3.8
N-SH2 PhPO4 1.4
a Tyr(P)751 peptide, SVDY(P)VPMLD; D-InsP4, D-myo-inositol
1,3,4,5-tetrakisphosphate; L-InsP4, L-myo-inositol 1,3,4,5-tetrakisphos-
phate; D-InsP3, D-myo-inositol 1,4,5-trisphosphate; PhPO4, phenyl
phosphate.
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as competitors of the association of PI 3-kinase with tyrosine-
phosphorylated proteins and as regulators of other SH2 do-
main-containing proteins, e.g. Src and phospholipase C g-1 (21,
22). Although the SH2 domain-mediated phosphoinositide-de-
pendent regulation of p85a/p110a, Src, or phospholipase C
activity has interesting implications, it is a model yet to be
clearly established.
Therefore, our primary experimental aim was to discover
whether the p85a N- and C-SH2 domains can bind to distinct
phosphoinositides with high affinity, specificity, and stereos-
electivity. Furthermore, we investigated whether the well de-
fined interactions between the p85a SH2 domains and Tyr(P)-
containing ligands could be competed by phosphoinositides or
inositol polyphosphates. We tested both phosphoinositides and
inositol polyphosphates as potential ligands of SH2 domains.
Inositol polyphosphates were in part used as conveniently wa-
ter-soluble analogues of the head groups of phosphoinositides
but may also represent physiological ligands. In our opinion
this usage of inositol polyphosphates is valid because protein-
phosphoinositide interactions appear to be predominantly gov-
erned by the charge status, phosphorylation positions, and
stereochemistry of the inositol ring (42, 44, 45). For example, it
has been demonstrated that D-Ins (1,4,5)P3 can functionally
replace PtdIns (4, 5)P2 in the activation of the dynamin GTPase
(35) and that the Btk PH domain binds specifically to both
D-Ins (1,3,4,5)P4 and PtdIns (3,4,5)P3 (35, 41) in vitro and to
PtdIns (3,4,5)P3 in vivo (15).
In search of specific phosphoinositide binding preferences of
the p85a SH2 domains, we chose to compare their interactions
with D-Ins (1,4,5)P3 and D-Ins (1,3,4,5)P4 or PtdIns (4,5)P2 and
PtdIns (3,4,5)P3. This choice was based on the knowledge that
PtdIns (4,5)P2 is abundant in the plasma membrane of resting
cells, whereas PtdIns (3,4,5)P3 is only present in appreciable
quantities after cell stimulation (8, 9). We also compared the
binding of the p85a SH2 domains to the physiological D- and
nonphysiological L-enantiomers of the inositol polyphosphates,
because stereoselectivity should be exhibited in the case of
true, biological interactions.
We observed that numerous different phosphoinositides and
inositol polyphosphates can bind to the p85a SH2 domains,
albeit weakly. Using NMR spectroscopy, we found that di-C6-
PIP3 and all the inositol polyphosphates tested bound to the
SH2 domains in the Tyr(P) binding pockets that accommodate
protein ligands. However, the SH2 domains failed to display
clear preferences for distinct phosphoinositides or inositol
polyphosphates presented in solution. Similarly, the C-SH2
domain did not demonstrate a distinct binding specificity for
phosphoinositides presented in phospholipid bilayers. Surface
representations of the SH2 domain structures that display
their calculated electrostatic potentials show that the Tyr(P)
binding pockets of the N- and particularly of the C-SH2 do-
mains are highly positively charged. Thus, the lack of binding
specificity or stereoselectivity shown by the SH2 domains for
the test ligands may reflect the likelihood that their interaction
is largely based on electrostatic interactions that have little
dependence on distinct structural features. Such interactions
are thus very different from those of high specificity observed
between SH2 domains and physiological Tyr(P)-containing
ligands.
In addition, in a competition assay we observed that despite
an overlap of binding sites, phosphoinositides and inositol
polyphosphates only poorly displaced SH2 domains from a
Tyr(P) peptide ligand. Furthermore, among the ligands tested,
there was no significant variation in the efficacy of competition.
From this assay, it also emerged that the N-SH2 domain bound
to di-C6-PIP3 and inositol polyphosphates similarly to, but even
more weakly than, the C-SH2 domain. This observation may
perhaps be explained by two factors. First, the Tyr(P) binding
pocket produces a greater density of positive charge on the
surface of the C-SH2 domain compared with the surface of the
N-SH2 domain (see Fig. 2), thus favoring interactions of the
former with negatively charged ligands. Second, it has been
observed that the unoccupied Tyr(P) binding pocket of the
C-SH2 domain is relatively exposed, whereas that of the N-SH2
domain is not fully formed in the absence of a peptide ligand
(39) and may therefore be less accessible to phosphoinositides.
However, the similar patterns of ligand binding observed for
both p85a SH2 domains suggest that all the ligands contact the
SH2 domains in the same, rather nonspecific manner. We
conclude that although in vitro both p85a SH2 domains may
interact weakly with PtdIns (3,4,5)P3 and inositol polyphos-
phates, the lack of specificity of these interactions and their
FIG. 5. Lack of correlation of p85-phosphotyrosine interac-
tions with wortmannin treatment. Wortmannin, a PI 3-kinase cat-
alytic domain inhibitor, does not promote the association of p85a with
the PDGF receptor or, more generally, with tyrosine-phosphorylated
proteins. Serum-starved NIH3T3 fibroblasts were treated with wort-
mannin (Wort, 100 nM) or Me2SO (vehicle) for 15 min and stimulated
with PDGF (100 nM) for 10 min, and cell lysates were immunoprecipi-
tated with anti-PDGF receptor (Ippt a-PDGFR, A) or anti-phosphoty-
rosine (Ippt a-PY, B and C) antibodies and protein G-Sepharose. A and
B, anti-phosphotyrosine immunoprecipitates were analyzed by SDS-
polyacrylamide gel electrophoresis and anti-p85a immunoblotting. C,
the immunoprecipitates were assayed for PI 3-kinase activity. Radio-
active lipids were analyzed by TLC. The results are representative of
three independent experiments.
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inability to compete effectively with Tyr(P) peptide ligands
suggest that they do not represent physiologically significant
interactions. Rather, it seems that in vitro the SH2 domain
Tyr(P) binding pocket has a tendency to bind somewhat indis-
criminately to negatively charged ligands. This promiscuity is
further witnessed in a crystal form of the p85a C-SH2 domain
in which the Tyr(P) binding pocket accommodates an aspartate
side chain.2 Although the mode of interaction is highly remi-
niscent of Tyr(P) binding (coordination of the aspartate carbox-
ylate group with both R36 and R18), the aspartate side chain is
clearly not a consensus ligand.
Finally, we demonstrated that although in vivo, wortmannin
blocks the activity of PI 3-kinase, it does not affect the ability of
activated PDGF receptors (or other tyrosine-phosphorylated
proteins) to bind the p85a regulatory subunit. These results are
in agreement with characterizations of wortmannin activity
(46) but contrast with previous reports of an inverse correlation
between the level of 39-phosphorylated phosphoinositides in the
cell and the association of PI 3-kinase with tyrosine-phospho-
rylated proteins (insulin receptor and insulin receptor sub-
strate) (21). Therefore we suggest the levels of PI 3-kinase
products in the plasma membrane are unlikely to regulate
signal transduction events through interactions with SH2 do-
mains. Rather, we consider that the immediate targets of PI
3-kinase activity are represented by those proteins that display
high affinity, distinct binding specificity, and stereoselectivity
for 39-phosphorylated phosphoinositides, such as the PH do-
main-containing proteins Akt, Btk, PDK-1, and phospholipase
C g-1.
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